Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Sector: Medicinal Chemicals & Botanical Products
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 134.37M shares outstanding
USDefinium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.
Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder.
The company maintains its headquarters in New York, New York.
Andreas Krebs
Vice Board Chair; Vice Chair of the Board
Brandi L. Roberts
Chief Financial Officer
Carol A. Vallone
Board Chair; Chair of the Board
Daniel Karlin, M.D., M.A.
Chief Medical Officer
Employees
106
Country
US
Sector
Healthcare
Website
definiumtx.com
Loading congressional disclosures…
based on 134.37M shares outstanding
US30d Avg
2.67M
60d Avg
2.17M
90d Avg
2.14M
